Asthma

The 2019 CHEST Meeting in New Orleans may be headlined by newly approved therapies including dupilumab and tezepelumab.

Using data registries from initial trials, companies such as Actelion will be looking to expand research beyond the first first or second year of care in patients with PAH.

Recent trials have evidenced that minority patient groups in particular are more likely to worsen their primary treatment adherence while embracing alternative medicine measures.

Once physicians know if it's the cause of PAH or just simply an overlap, comorbidities have to be closely monitored as disease progression.

Clinical research has begun to distinguish biomarkers for both conditions, research has established their similarities, and therapies are becoming pathway-based. Should asthma-COPD diagnoses be necessary?

Investigators from the Nationwide Children’s Hospital assessed family history in relation to asthma control in pediatric patients.

Montelukast/levocetirizine combination therapy demonstrates safety and efficacy in phase 3 clinical trial for the treatment of patients with perennial allergic rhinitis who have mild-to-moderate asthma.

Before biologics are implemented, what should physicians be doing to ensure asthma control in their patients?

The addition of a couple of new drug classes at the turn of the century have given clinicians the greenlight to stack therapies at initial treatment.

There’s a challenge to achieve control in some asthma patients since the disease is heterogenous—both allergic and non-allergic triggers can initiate Type 2 inflammatory pathways that can drive pathology.

Joshua Denson, MD, MS, discusses the comorbidities associated with asthma.

Now that real-world data registries are being compiled, the constriction-limiting drug class is now going through personalizations including new titration strategies.

What makes the monoclonal antibody so enticing to the asthma community?

A 200 mg dose of the monoclonal antibody was also shown to significantly reduce ashtma exacerbations over 1 year versus placebo.

A retrospective review of rural region's hospitals found that even the discharge time of day could be associated with a greater chance of readmission.

Gram-negative bacteria excluding Pseudomonas Aeruginosa has been associated with greater rates of patient mortality, vasopressor administration, and ICU admission.

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

Secondhand factors in asthma, such as environmental exposures like pets and secondhand smoke, are not significant in overall disease improvement.

Investigators have shared new disparities of characteristics in men and women with differing severities of respiratory arousal threshold.

A new study found that Medicare Part D formulary shifts sometimes result in asthma patients forgoing controller therapy altogether.

The association between moderate hyperbilirubinemia and childhood asthma and lack of association with higher bilirubin levels indicates the association is not causal.

It’s long been established that obesity can lead to asthma, but new research suggests asthma can also lead to obesity.

Upon finding pH and oxygen may influence how antibiotics perform in CF lung infections, investigators suggest a one-size-fits-all therapy approach may not be the best treatment.

The pulmonologist and senior medical advisor, American Lung Association, highlights the necessary steps of smoking cessation practices as well as the unknown surrounding e-cigarettes.

The new formulation, known as Xolair PFS, will be available in the US by the end of the year.